THANK YOU FOR SUBSCRIBING
Following their proclivity toward adopting and utilizing the latest, cutting-edge technologies for the betterment of patient care delivery, healthcare professionals today have begun incorporating a slew of new digital practices in their daily workflows. Among the many innovative forms of medical technology utilized throughout healthcare facilities, like EHR systems and wearables, evidence-based medicine (EBM) is becoming one of the most useful tools in driving the best clinical outcomes across the industry. EBM integrates a physician’s or health system’s experience and their patient’s values with the best available research information, which consequently increases the resourcefulness of high-quality clinical research for medical decision making. With the help of EBM practices, healthcare organizations across the globe can streamline and bolster patient care delivery efficiently and cost-effectively. However, EBM is heavily dependent on data, and data scientists understand the technology better than the physicians in a health system. Translating the necessary information can become tedious, and the chances of miscommunicating important details about a patient’s condition may increase. To help physicians and large hospitals avoid such situations and deliver the best possible care, FRONTEO, a comprehensive healthcare technology and business enterprise, offers AI-based solutions that strive to drive the most out of modern medicine.
“With the aid of our domain experts, we offer consultation and advanced AI-based data analysis services to help bridge the gap between data scientists and health systems. Our service is a complete package of consultations consisting of data, algorithms, outputs, and system integrations,” expresses Hiroyoshi Toyoshiba, research director and CTO of FRONTEO’s Life Science AI Business Division.
The company also offers three distinctive services, where its AI-based Diagnosis Support gathers information from various conversations between patients and their respective physicians. For instance, a doctor can administer a mini-mental state exam (MMSE), and FRONTEO’s ML capabilities provide healthcare professionals with the possibility of quickly detecting Mild Cognitive Impairment (MCI) and dementia. The company’s Healthcare Operational Support service analyses hospital incident reports, including data on patient conditions from electronic folders as well as the text data of free comments found in daily records of examination and treatment. This allows the AI to calculate, predict, and identify patients who have a high fall risk in a hospital. Lastly, as a Pharmaceutical Industry Support service, the company’s AI aids drug discovery and enables the analysis of various text data with the aim of making pharmacovigilance work more efficient, while delivering high quality of data. This system is being further developed to predict causal or responsive genes when a disease name is provided as a query, generating a molecular map linking the gene’s sets. “We also offer a solution that automatically classifies official documents from the government into groups that are most relevant,” says Toyoshiba.
Moving forward, the company aims to penetrate healthcare markets beyond the borders of Japan. Owing to the country’s advanced ageing society, FRONTEO is also going to focus its efforts toward developing dementia diagnosis support systems, based on neuro-linguistic programming (NLP) and have them approved as patented medical devices to help improve drug discovery across the globe.